CTMX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.90%

Insider Buying (Last 12 Months): $7,750.00

Insider Selling (Last 12 Months): $61,800.12

CytomX Therapeutics Insider Trading History Chart

CytomX Therapeutics Share Price & Price History

^$1.41

▲ +0.02 (1.44%)

As of 12/1/2023 01:00 AM ET

Days: 30 | 90 | 365

Trading Experts Call It “The Perfect Tesla Trade”

From Wealthpress | Ad

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

Click here for details,

CytomX Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/22/2023	Lloyd A Rowland	General Counsel	Sell	5,486	$1.30	$7,131.80	80,609
9/22/2023	Marcia Belvin	SVP	Sell	4,119	$1.30	$5,354.70	147,951
9/22/2023	Sean A. McCarthy	CEO	Sell	14,601	$1.30	$18,981.30	430,755
3/29/2023	Elaine V Jones	Director	Buy	5,000	$1.55	$7,750.00	5,142
3/16/2023	Amy C Peterson	EVP	Sell	4,257	$1.98	$8,428.86	58,433
3/16/2023	Carlos Campoy	CFO	Sell	1,748	$1.98	$3,461.04	38,224
3/16/2023	Christopher Ogden	SVP	Sell	516	$1.98	$1,021.68	37,772
3/16/2023	Lloyd A Rowland	General Counsel	Sell	2,037	$1.98	$4,033.26	71,095
3/16/2023	Sean A. McCarthy	CEO	Sell	7,121	$1.88	$13,387.48	388,821
7/20/2022	Amy C Peterson	EVP	Sell	7,463	$1.42	$10,597.46	62,690
7/20/2022	Carlos Campoy	CFO	Sell	3,949	$1.42	$5,607.58	39,972
7/20/2022	Jeffrey B Landau	Insider	Sell	4,206	$1.42	$5,972.52	30,725
7/20/2022	Lloyd A Rowland	General Counsel	Sell	5,602	$1.42	$7,954.84	43,689
7/20/2022	Sean A. McCarthy	CEO	Sell	14,911	$1.42	$21,173.62	290,942
6/16/2021	Sean A. McCarthy	CEO	Sell	100,000	$7.04	$704,000.00	7,849
3/31/2021	Sean A. McCarthy	CEO	Sell	100,000	$7.49	$749,000.00	306,894

New CBOE “special perk” helps traders target income every weekend

From DTI Trader | Ad

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

Check out this training for the full story!

SEC Filings (Institutional Ownership Changes) for CytomX Therapeutics (NASDAQ:CTMX)

51.11% of CytomX Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

CytomX Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/17/2023	Jacobs Levy Equity Management Inc.	1,052,105	$1.36M	0.0%	-35.1%	1.571%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	145,934	$0.19M	0.0%	-6.5%	0.218%
11/13/2023	FMR LLC	707,968	$0.91M	0.0%	-2.7%	1.057%
11/6/2023	Assenagon Asset Management S.A.	425,921	$0.55M	0.0%	-36.2%	0.638%
10/24/2023	Bank of New York Mellon Corp	266,836	$0.34M	0.0%	+737.4%	0.400%
8/14/2023	Marshall Wace LLP	674,501	$1.16M	0.0%	-7.6%	1.010%
8/11/2023	Renaissance Technologies LLC	1,122,400	$1.93M	0.0%	+32.0%	1.681%
8/11/2023	BlackRock Inc.	1,147,816	$1.97M	0.0%	+2.1%	1.719%
8/8/2023	Bronte Capital Management Pty Ltd.	925,245	$1.59M	0.2%	+0.8%	1.395%
7/31/2023	LPL Financial LLC	98,265	$0.17M	0.0%	+67.2%	0.148%
7/14/2023	Congress Park Capital LLC	106,150	$0.18M	0.1%	+5.9%	0.160%
5/23/2023	Toroso Investments LLC	318,111	$0.48M	0.0%	-8.0%	0.480%
5/16/2023	State Street Corp	267,476	$0.40M	0.0%	+19.4%	0.403%
5/16/2023	Squarepoint Ops LLC	48,856	$74K	0.0%	N/A	0.074%
5/16/2023	Geode Capital Management LLC	642,308	$0.97M	0.0%	+6.5%	0.968%
5/15/2023	Two Sigma Advisers LP	516,100	$0.78M	0.0%	-1.7%	0.778%
5/15/2023	Two Sigma Investments LP	467,616	$0.71M	0.0%	-36.9%	0.705%
5/15/2023	XTX Topco Ltd	17,815	$27K	0.0%	-39.8%	0.027%
5/12/2023	Renaissance Technologies LLC	850,300	$1.28M	0.0%	-36.6%	1.282%
5/12/2023	BlackRock Inc.	1,123,772	$1.70M	0.0%	-13.6%	1.694%
5/12/2023	UBS Group AG	26,793	$40K	0.0%	-41.5%	0.040%
5/12/2023	Dimensional Fund Advisors LP	156,456	$0.24M	0.0%	-9.3%	0.236%
5/12/2023	Tejara Capital Ltd	157,928	$0.24M	0.1%	-33.1%	0.238%
5/12/2023	Charles Schwab Investment Management Inc.	24,817	$37K	0.0%	-41.2%	0.037%
5/11/2023	Cornercap Investment Counsel Inc.	82,415	$0.12M	0.0%	-44.4%	0.124%
5/11/2023	FMR LLC	705,697	$1.07M	0.0%	-1.5%	1.064%
5/10/2023	Private Advisor Group LLC	73,179	$0.11M	0.0%	N/A	0.110%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	134,309	$0.20M	0.0%	-11.1%	0.202%
5/9/2023	Tower Research Capital LLC TRC	45,351	$69K	0.0%	+37.0%	0.068%
5/1/2023	Virtu Financial LLC	24,136	$36K	0.0%	N/A	0.036%
4/20/2023	Congress Park Capital LLC	100,200	$0.15M	0.1%	N/A	0.151%
4/18/2023	Assenagon Asset Management S.A.	668,032	$1.01M	0.0%	-27.0%	1.009%
2/15/2023	Jane Street Group LLC	41,559	$66K	0.0%	N/A	0.063%
2/15/2023	Toroso Investments LLC	345,905	$0.55M	0.0%	+11.1%	0.523%
2/15/2023	Tejara Capital Ltd	236,050	$0.38M	0.2%	N/A	0.357%
2/15/2023	Tang Capital Management LLC	3,510,445	$5.62M	0.8%	+0.3%	5.312%
2/15/2023	Millennium Management LLC	1,719,811	$2.75M	0.0%	+223.0%	2.602%
2/15/2023	Man Group plc	34,575	$55K	0.0%	+36.0%	0.052%
2/14/2023	Verition Fund Management LLC	27,296	$44K	0.0%	N/A	0.041%
2/14/2023	Cetera Investment Advisers	20,000	$32K	0.0%	N/A	0.030%
2/14/2023	Alpine Global Management LLC	47,723	$76K	0.0%	+304.4%	0.072%
2/14/2023	Two Sigma Investments LP	740,724	$1.19M	0.0%	+106.9%	1.121%
2/13/2023	Platinum Investment Management Ltd.	635,798	$1.02M	0.0%	-48.3%	0.962%
2/13/2023	Forefront Analytics LLC	24,787	$40K	0.0%	-48.2%	0.038%
2/13/2023	Renaissance Technologies LLC	1,340,774	$2.15M	0.0%	-25.7%	2.029%
2/13/2023	Geode Capital Management LLC	603,075	$0.96M	0.0%	+2.7%	0.913%
2/10/2023	Bank of America Corp DE	42,009	$67K	0.0%	+221.0%	0.064%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	151,020	$0.24M	0.0%	-28.3%	0.229%
2/9/2023	CM Management LLC	75,000	$0.12M	0.1%	N/A	0.113%
2/9/2023	Dimensional Fund Advisors LP	172,572	$0.28M	0.0%	-4.4%	0.261%
2/8/2023	UBS Group AG	45,800	$73K	0.0%	+157.4%	0.069%
2/7/2023	Commonwealth Equity Services LLC	53,243	$85K	0.0%	N/A	0.081%
2/7/2023	Formidable Asset Management LLC	318,233	$0.51M	0.1%	+2.2%	0.482%
2/1/2023	Bank of Montreal Can	69,600	$0.12M	0.0%	N/A	0.105%
1/12/2023	Assenagon Asset Management S.A.	914,900	$1.46M	0.0%	-14.1%	1.384%
1/10/2023	FNY Investment Advisers LLC	65,000	$0.10M	0.1%	N/A	0.098%
11/23/2022	Toroso Investments LLC	311,315	$0.45M	0.0%	+49.8%	0.471%
11/15/2022	Public Employees Retirement System of Ohio	82,028	$0.12M	0.0%	N/A	0.124%
11/15/2022	Jacobs Levy Equity Management Inc.	1,094,318	$1.59M	0.0%	+22.1%	1.656%
11/15/2022	Tang Capital Management LLC	3,500,000	$5.08M	0.6%	+231.9%	5.296%
11/15/2022	Two Sigma Advisers LP	527,400	$0.77M	0.0%	+36.3%	0.798%
11/15/2022	Two Sigma Investments LP	357,961	$0.52M	0.0%	+20.2%	0.542%
11/15/2022	Vanguard Group Inc.	4,537,961	$6.58M	0.0%	-10.6%	6.867%
11/15/2022	Marshall Wace LLP	40,021	$58K	0.0%	-37.6%	0.061%
11/15/2022	Formidable Asset Management LLC	311,315	$0.45M	0.1%	+49.8%	0.471%
11/15/2022	BVF Inc. IL	6,595,801	$9.56M	0.4%	+13.6%	9.982%
11/15/2022	BlackRock Inc.	1,799,363	$2.61M	0.0%	-1.5%	2.723%
11/14/2022	Renaissance Technologies LLC	1,805,600	$2.62M	0.0%	+24.2%	2.732%
11/14/2022	Ergoteles LLC	279,056	$0.41M	0.0%	-12.2%	0.422%
11/14/2022	Forefront Analytics LLC	47,869	$71K	0.0%	+33.3%	0.072%
11/10/2022	Dimensional Fund Advisors LP	180,580	$0.26M	0.0%	-54.5%	0.274%
11/10/2022	Tower Research Capital LLC TRC	25,728	$37K	0.0%	+125.0%	0.039%
11/10/2022	UBS Group AG	17,793	$26K	0.0%	+322.8%	0.027%
11/9/2022	Magnus Financial Group LLC	20,000	$29K	0.0%	N/A	0.030%
11/8/2022	AlphaCentric Advisors LLC	257,500	$0.37M	0.4%	N/A	0.390%
11/4/2022	Russell Investments Group Ltd.	61,320	$88K	0.0%	-74.0%	0.093%
10/27/2022	Assenagon Asset Management S.A.	1,065,392	$1.55M	0.0%	N/A	1.615%
8/22/2022	ExodusPoint Capital Management LP	162,990	$0.30M	0.0%	+499.7%	0.247%
8/18/2022	Goldman Sachs Group Inc.	187,542	$0.34M	0.0%	-75.3%	0.284%
8/16/2022	Formidable Asset Management LLC	207,772	$0.38M	0.1%	N/A	0.315%
8/16/2022	Price T Rowe Associates Inc. MD	633,418	$1.16M	0.0%	-4.2%	0.960%
8/16/2022	Prudential Financial Inc.	19,700	$36K	0.0%	N/A	0.030%
8/15/2022	AQR Capital Management LLC	391,860	$0.72M	0.0%	N/A	0.594%
8/15/2022	State Street Corp	223,976	$0.41M	0.0%	-81.3%	0.340%
8/15/2022	Clearline Capital LP	196,583	$0.36M	0.0%	+3.1%	0.298%
8/15/2022	Point72 Asset Management L.P.	2,750,000	$5.03M	0.0%	-37.1%	4.170%
8/15/2022	Laurion Capital Management LP	1,270,900	$2.33M	0.0%	N/A	1.927%
8/15/2022	Millennium Management LLC	1,441,732	$2.64M	0.0%	-35.8%	2.186%
8/15/2022	Knightsbridge Asset Management LLC	96,926	$0.18M	0.0%	N/A	0.147%
8/13/2022	Renaissance Technologies LLC	1,454,261	$2.66M	0.0%	+62.3%	2.205%
8/12/2022	Northern Trust Corp	112,482	$0.21M	0.0%	-80.4%	0.171%
8/12/2022	LPL Financial LLC	34,740	$64K	0.0%	N/A	0.053%
8/12/2022	BNP Paribas Arbitrage SA	19,318	$35K	0.0%	+254.2%	0.029%
8/12/2022	Franklin Resources Inc.	34,084	$62K	0.0%	-32.7%	0.052%
8/11/2022	Platinum Investment Management Ltd.	1,229,545	$2.25M	0.1%	+25.5%	1.864%
8/10/2022	Gladius Capital Management LP	13,172	$25K	0.0%	N/A	0.020%
8/10/2022	Forefront Analytics LLC	35,919	$67K	0.0%	+145.3%	0.054%
8/9/2022	Pictet Asset Management SA	660,495	$1.21M	0.0%	+87.0%	1.002%
8/5/2022	Connor Clark & Lunn Investment Management Ltd.	207,071	$0.38M	0.0%	+3.4%	0.317%
7/29/2022	Russell Investments Group Ltd.	235,470	$0.43M	0.0%	+175.8%	0.360%

Data available starting January 2016

CytomX Therapeutics, Inc., a clinical-stage, oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company's pipeline comprises therapeutic candidates across multiple treatment modalities, including antibody-drug conjugates (ADCs), T-cell engaging bispecific antibodies, and immune modulators, such as cytokines and checkpoint inhibitors. CX-2029 is an investigational conditional ADC directed toward CD71. Its clinical pipeline also includes cancer immunotherapeutic candidates against validated targets, such as the CTLA-4-targeting Probody therapeutic BMS-986288, partnered with Bristol Myers Squibb, as well as CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. In addition, it has a preclinical portfolio of wholly owned assets, including CX-801, an interferon alpha-2b Probody cytokine that has potential applicability in immuno-oncology sensitive, as well as insensitive (cold) tumors and CX-2051, an ADC directed toward EpCAM with potential applicability across multiple EpCAM-expressing epithelial cancers. The company has strategic collaborations with various leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. The company was founded in 2008 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.41

$1.36

$1.43

50 Day Range

MA: $1.26

$1.07

$1.41

52 Week Range

Now: $1.41

$1.04

$3.02

Volume

204,112 shs

Average Volume

931,489 shs

Market Capitalization

$94.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Who are the company insiders with the largest holdings of CytomX Therapeutics?: CytomX Therapeutics' top insider investors include:
Sean A Mccarthy (CEO)
Marcia Belvin (SVP)
Lloyd A Rowland (General Counsel)
Amy C Peterson (EVP)
Carlos Campoy (CFO)
Christopher Ogden (SVP)
Jeffrey B Landau (Insider)
Elaine V Jones (Director)
Learn More about top insider investors at CytomX Therapeutics.
Who are the major institutional investors of CytomX Therapeutics?: CytomX Therapeutics' top institutional investors include:
Jacobs Levy Equity Management Inc. — 1.57%
FMR LLC — 1.06%
Assenagon Asset Management S.A. — 0.64%
Bank of New York Mellon Corp — 0.40%
Connor Clark & Lunn Investment Management Ltd. — 0.22%
Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of CytomX Therapeutics stock.
Which institutional investors are selling CytomX Therapeutics stock?: During the previous quarter, CTMX stock was sold by these institutional investors:
Jacobs Levy Equity Management Inc.
Assenagon Asset Management S.A.
FMR LLC
Connor Clark & Lunn Investment Management Ltd.
In the last year, company insiders that have sold CytomX Therapeutics company stock include:
Sean A Mccarthy (CEO)
Marcia Belvin (SVP)
Lloyd A Rowland (General Counsel)
Amy C Peterson (EVP)
Carlos Campoy (CFO)
Christopher Ogden (SVP)
Learn More investors selling CytomX Therapeutics stock.
Which institutional investors are buying CytomX Therapeutics stock?: In the last quarter, CTMX stock was purchased by institutional investors including:
Bank of New York Mellon Corp